Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Mar 17, 2021 11:05am
159 Views
Post# 32816183

RE:Corner, bend, horizon....."Dredge Edge" ; - )

RE:Corner, bend, horizon....."Dredge Edge" ; - )Never mind your data, always mine it.

"Cytokine measurement pre and postPMXDHP revealed decreased levels of interleukin6 and the factors involved in vascular endothelial injury, including vascular endothelial growth factor."

(Who knew that use of PMX would result in decreased levels of what may be the nastiest of the cytokines, IL-6?.  I thought that was CTSO's job?  How's their non-existent Trial in the US going?  You just can't get good help these days.)

"PMXDHP may have a beneficial effect on patients with COVID19. Therefore, future prospective studies with a control group are expected to evaluate the therapeutic effect of PMXDHP in patients with COVID19."

Dec 15, 2020

https://onlinelibrary.wiley.com/doi/10.1002/jca.21861
<< Previous
Bullboard Posts
Next >>